Published By : 30 Mar 2016 | Published By : QYRESEARCH
The global market for hypertrophic cardiomyopathy therapeutics has experienced a healthy rise in the recent times. The increasing incidence of hypertrophic cardiomyopathy across the world has fueled this market significantly.
The growing awareness among patients about this therapy has also boosted its demand extensively in the global arena. However, technical advancements in several medical devices such as pacemakers and defibrillators are likely to propel their application for chronic cardiac diseases, limiting the usage of hypertrophic cardiomyopathy therapeutics in the near future. However, the introduction of novel targeted drugs is projected to open new success avenues for market players over the next few years.
Presence of Modern Healthcare Infrastructure Propels Hypertrophic Cardiomyopathy Therapeutics Market in Europe and North America
Primarily, the market is concentrated in North America. In 2014, this regional market acquired the dominating share of more than 30% in the overall market. Europe held the second position among all the regional markets the same year.
The presence of modern healthcare infrastructure, growing trend of inactive lifestyle among the youth, and the rapid rise in obese population are some of the prominent factors, driving the hypertrophic cardiomyopathy therapeutics market in North America and Europe. In addition to these, the increasing awareness about hypertrophic cardiomyopathy in developed economies is likely to propel both the regional markets.
Asia Pacific to report Fastest Growth in Global Hypertrophic Cardiomyopathy Therapeutics Market
Though North America is projected to maintain its dominance in the coming years, Asia Pacific is likely to exhibit the fastest growth among all the regional markets for hypertrophic cardiomyopathy therapeutics. The increase prevalence of hypertrophic cardiomyopathy, infrastructural advancement of the Asia Pacific healthcare industry, and the increased awareness among people pertaining to cardiac complications in this region is expected to stimulate the Asia Pacific hypertrophic cardiomyopathy therapeutics market.
Pfizer Inc., Merck & Co. Inc., Mylan N.V., Teva Pharmaceuticals, Astra Zeneca Plc, Concordia Healthcare Corp., Sanofi S.A., Novartis AG, and Gilead Sciences Inc. are the major enterprises working on the development of hypertrophic cardiomyopathy therapeutics across the world.